Hepcidin levels and their determinants in different types of myelodysplastic syndromes. - Test2 - elhamkhani - TriplyDB

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

http://www.wikidata.org/entity/Q34008796

about

Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes Mechanisms of mammalian iron homeostasis Molecular liaisons between erythropoiesis and iron metabolism A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome Is erythroferrone finally the long sought-after systemic erythroid regulator of iron?Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from Günther disease model.Myelodysplastic Syndromes and Iron Chelation Therapy Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.Deferasirox in a refractory anemia after other treatment options: case report and literature review.Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.New strategies to target iron metabolism for the treatment of beta thalassemia Iron chelation therapy in low risk myelodysplastic syndrome.Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.Diagnostic potential of hepcidin testing in pediatrics.Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?New insights on iron study in myelodysplasia Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15.Labile plasma iron levels predict survival in patients with lower-risk Myelodysplastic syndromes.Iron overload in myelodysplastic syndromes (MDS).Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications.Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes.The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.Myelodysplastic syndrome macrophages have aberrant iron storage and heme oxygenase-1 expression.

P2860

Q26765037-F831820A-B3DA-41FF-8943-F40AF433AB17 Q27010510-3426553F-8506-4B7B-9BBE-79439A598C91 Q33948684-20889094-3FBA-47BC-A4FC-5A41FA5BD3DD Q34235483-15BA85C2-3283-458C-807A-0AF7D89B1EBF Q34811179-35354A4B-9D30-419F-82B4-49BC2B06A9B4 Q35629409-5E5B5D67-D3EF-4CE3-A4C7-4238238B8622 Q35743810-701E3384-08AF-4CB9-84B7-982FD4386131 Q35996682-42C9AD53-B5DC-4260-BC88-ABB58352D8B5 Q36296712-C8CD2D38-2826-47CE-B474-D92D219ED4ED Q36862329-036C0A74-27C7-44EE-8DD6-92ECD11496CC Q37215937-1444370C-3AFE-4CD0-B3D8-6CDAC6A779A4 Q37618819-19B61259-4DB7-4845-B167-C85AF26CBE77 Q37677229-F70A649A-56E7-466B-AD9D-048BF007D6DE Q38196963-1A136D6F-BCFA-4CF0-BB6F-FE72D76F5EAC Q38368123-5B3CB0DA-AA67-4DB1-9032-5D5F9521C1A9 Q38416115-6700632F-F927-4698-A5FD-3212888E3A02 Q38549248-297332A7-66C8-4094-AAE4-F6B600047076 Q38613789-18EB72AF-C45A-480F-8FDD-9A372AB3F713 Q38751490-A5F77D6B-CEF2-4078-A4DE-84109AC83D02 Q38903926-E52941B2-F9EF-44D3-BBE1-097F0DDE0E3D Q39459295-69AC41F3-A42F-437B-B6E3-C698D6B8CDD3 Q39462117-0816D55D-8143-4F3A-BCFC-63D75F1263BD Q41240360-DDFB6DE8-1528-4F8A-86D2-A7923A2E1B22 Q41865932-12726517-033A-41F2-BEB5-42A1140CEA6F Q45132809-5E4C0B99-189E-41C7-8208-1683CF6C085E Q45883725-D86F73F5-C492-4AFD-B9CA-BC2C1749AB19 Q46264493-D115F877-42F0-4314-ADEA-5739C3C18961 Q47410460-1DCD5053-B3C2-43D6-985E-7EE5E218C24D Q48175966-E4034EEE-C723-4EC8-88A6-3E78AC4BDB2F Q49389245-98655686-7548-4169-B5AB-AB9980DFB4CC Q51790001-6711753A-2030-4ACA-9422-E8C9BD5560B2 Q53113161-C7436718-C793-4C2B-82F6-E54EB43DB87E Q53212345-E709E3D5-ADF8-4CEF-95C1-A3064F633DF2

P2860

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

http://www.wikidata.org/entity/Q34008796

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@ast

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@en

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@nl

type

label

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@ast

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@en

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@nl

prefLabel

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@ast

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@en

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@nl

P1433

Q34008796-77C4D6F8-51E1-442C-93E2-9FD382FB989E

P1476

Q34008796-C1D72973-9468-4E5B-B7B4-13E1A210F3B3

P2093

Q34008796-263B30F3-9888-4B98-BBF8-ABC94D7A9CDF

Q34008796-2BFEFAA9-FE17-4C73-82C5-0999F2BA3F3A

Q34008796-45EA0FB0-640F-4E36-94EB-3E3CB9D26A44

Q34008796-47A04134-568D-40F5-BA64-624B2BBB1EC2

Q34008796-4F531685-7E48-4B75-A06F-88509F7E8449

Q34008796-59A0A77A-403F-4400-A97A-6F9B0CFE58C1

Q34008796-7571C2EF-A885-47D1-BFC1-F3482EB61C5A

Q34008796-C8DEAA1D-3EC2-4B62-9409-5C59786AF6BF

Q34008796-D74449AB-F5E4-48E0-9778-AC5A60B23512

Q34008796-DB434756-844F-4F3A-AF4A-BB1F40A1BF66

P2860

Q34008796-032A1EF8-F16D-4836-8A7D-FBBBB52E223C

Q34008796-039650E7-B6FA-465D-B347-9EC1930871A8

Q34008796-08FE3B42-42CA-4092-B2FF-6FD56B772EA5

Q34008796-13E34F2A-3795-4A6D-A5C2-66F309C54B0E

Q34008796-17D05921-DF3C-479B-B176-6D69681B1541

Q34008796-1DAF7A21-22C8-425D-9EB9-15EEA28DA6D8

Q34008796-2BBE4DB1-9679-42B1-A693-0BE67A623284

Q34008796-2CD58ECF-D10B-437A-AE7E-756FC6AD4FB5

Q34008796-2EB0613E-D9FE-4DFC-AB89-AEFCD210E0D5

Q34008796-3068EB0A-E059-4F2B-B035-79E8E7A36F0F

P304

Q34008796-F6108B74-243C-4EFF-B096-86707354425F

P31

Q34008796-D54581E9-874F-4AB3-B4D0-9E2E4A45903D

P356

Q34008796-408A7EC3-C258-44BE-8F60-9B7668904B2A

P407

Q34008796-C5E64B83-389D-4FEC-9D02-C73DBBAB0A8F

P433

Q34008796-E592F205-F750-46C8-A3A3-185A159AABA7

P478

Q34008796-5E7ECC42-66C8-436B-B3C3-6F4EA657B80B

P50

Q34008796-E196E94B-E67A-4B23-B0C5-D6BAAD56BB5A

P577

Q34008796-BE872876-EC61-405D-935E-7E5687CC5324

P5875

Q34008796-E22107A2-A7E2-4ACF-8C64-3A7087B0F96F

P698

Q34008796-BD55EB6A-42C4-45BB-A163-C03B68B3FA07

P932

Q34008796-4C31A2A1-1E98-42C4-964A-B1C517CEA1BC

P356

JOURNAL.PONE.0023109

P1433

P1476

Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

@en

P2093

Agostino Cortelezzi

http://www.w3.org/2001/XMLSchema#string

Alberto Bosi

http://www.w3.org/2001/XMLSchema#string

Alessandro Sanna

http://www.w3.org/2001/XMLSchema#string

Domenico Girelli

http://www.w3.org/2001/XMLSchema#string

Gianluigi Reda

http://www.w3.org/2001/XMLSchema#string

Lorena Duca

http://www.w3.org/2001/XMLSchema#string

Maria Domenica Cappellini

http://www.w3.org/2001/XMLSchema#string

Michela Corbella

http://www.w3.org/2001/XMLSchema#string

Natascia Campostrini

http://www.w3.org/2001/XMLSchema#string

Oliviero Olivieri

http://www.w3.org/2001/XMLSchema#string

P2860

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily

A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis

The World Health Organization (WHO) classification of the myeloid neoplasms

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein

The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis

Two to tango: regulation of Mammalian iron metabolism

Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry

Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis.

HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.

P304

e23109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0023109

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Nicola Martinelli

P577

2011-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51614440

http://www.w3.org/2001/XMLSchema#string

P698

21886780

http://www.w3.org/2001/XMLSchema#string

P932

3158762

http://www.w3.org/2001/XMLSchema#string